O'Shaughnessy Asset Management’s Charles River Laboratories CRL Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $437K | Sell |
1,927
-1,818
| -49% | -$324K | ﹤0.01% | 1659 |
|
|
2026
Q1 | $646K | Buy |
3,745
+842
| +29% | +$156K | ﹤0.01% | 1403 |
|
|
2025
Q4 | $579K | Buy |
2,903
+465
| +19% | +$84.3K | ﹤0.01% | 1419 |
|
|
2025
Q3 | $381K | Buy |
2,438
+425
| +21% | +$67.5K | ﹤0.01% | 1624 |
|
|
2025
Q2 | $305K | Sell |
2,013
-871
| -30% | -$116K | ﹤0.01% | 1619 |
|
|
2025
Q1 | $434K | Buy |
2,884
+566
| +24% | +$94.9K | ﹤0.01% | 1388 |
|
|
2024
Q4 | $428K | Sell |
2,318
-501
| -18% | -$96.5K | ﹤0.01% | 1350 |
|
|
2024
Q3 | $544K | Buy |
2,819
+476
| +20% | +$98.9K | ﹤0.01% | 1191 |
|
|
2024
Q2 | $484K | Buy |
2,343
+813
| +53% | +$184K | 0.01% | 1145 |
|
|
2024
Q1 | $415K | Buy |
+1,530
| New | +$365K | ﹤0.01% | 1183 |
|
|
2023
Q3 | – | Sell |
-1,170
| Closed | -$246K | – | 1633 |
|
|
2023
Q2 | $246K | Buy |
+1,170
| New | +$233K | ﹤0.01% | 1134 |
|
|
2023
Q1 | – | Sell |
-1,262
| Closed | -$275K | – | 1497 |
|
|
2022
Q4 | $275K | Buy |
+1,262
| New | +$276K | ﹤0.01% | 1002 |
|
|
2022
Q3 | – | Sell |
-1,279
| Closed | -$274K | – | 1347 |
|
|
2022
Q2 | $274K | Buy |
1,279
+460
| +56% | +$112K | 0.01% | 905 |
|
|
2022
Q1 | $233K | Sell |
819
-705
| -46% | -$217K | ﹤0.01% | 1007 |
|
|
2021
Q4 | $574K | Sell |
1,524
-231
| -13% | -$89.7K | 0.01% | 658 |
|
|
2021
Q3 | $725K | Buy |
1,755
+364
| +26% | +$151K | 0.01% | 557 |
|
|
2021
Q2 | $514K | Buy |
1,391
+587
| +73% | +$196K | 0.01% | 644 |
|
|
2021
Q1 | $233K | Sell |
804
-10
| -1% | -$2.78K | 0.01% | 870 |
|
|
2020
Q4 | $203K | Buy |
814
+305
| +60% | +$72.6K | 0.01% | 821 |
|
|
2020
Q3 | $115K | Buy |
509
+434
| +579% | +$90.1K | ﹤0.01% | 859 |
|
|
2020
Q2 | $13K | Buy |
+75
| New | +$12K | ﹤0.01% | 1209 |
|
|
2020
Q1 | – | Sell |
-20
| Closed | -$3K | – | 1389 |
|
|
2019
Q4 | $3K | Buy |
+20
| New | +$2.77K | ﹤0.01% | 1561 |
|
|
2018
Q4 | – | Sell |
-24,622
| Closed | -$3.31M | – | 936 |
|
|
2018
Q3 | $3.31M | Sell |
24,622
-5,449
| -18% | -$673K | 0.07% | 153 |
|
|
2018
Q2 | $3.38M | Sell |
30,071
-696
| -2% | -$75.2K | 0.07% | 159 |
|
|
2018
Q1 | $3.28M | Buy |
30,767
+468
| +2% | +$50.4K | 0.07% | 146 |
|
|
2017
Q4 | $3.32M | Buy |
30,299
+27,846
| +1,135% | +$3.03M | 0.08% | 149 |
|
|
2017
Q3 | $265K | Buy |
+2,453
| New | +$252K | 0.01% | 470 |
|
|
2016
Q2 | – | Sell |
-1,374
| Closed | -$104K | – | 928 |
|
|
2016
Q1 | $104K | Sell |
1,374
-366
| -21% | -$27.1K | ﹤0.01% | 539 |
|
|
2015
Q4 | $140K | Sell |
1,740
-2,844
| -62% | -$205K | ﹤0.01% | 515 |
|
|
2015
Q3 | $291K | Hold |
4,584
| – | – | 0.01% | 440 |
|
|
2015
Q2 | $322K | Sell |
4,584
-119
| -3% | -$8.81K | 0.01% | 436 |
|
|
2015
Q1 | $372K | Buy |
4,703
+387
| +9% | +$28.6K | 0.01% | 419 |
|
|
2014
Q4 | $273K | Hold |
4,316
| – | – | 0.01% | 491 |
|
|
2014
Q3 | $257K | Sell |
4,316
-78
| -2% | -$4.46K | ﹤0.01% | 511 |
|
|
2014
Q2 | $235K | Buy |
4,394
+1,389
| +46% | +$76.2K | ﹤0.01% | 539 |
|
|
2014
Q1 | $181K | Buy |
+3,005
| New | +$175K | ﹤0.01% | 562 |
|
Other funds holding CRL
AI
O'Shaughnessy Asset Management's CRL Position: Q2 2026 in Review
O'Shaughnessy Asset Management reduced its Charles River Laboratories (CRL) stake by 49% in Q2 2026, selling an estimated $324K and leaving 1,927 shares worth $437K. The position accounts for ﹤0.01% of the portfolio, ranked #1659.
O'Shaughnessy Asset Management first reported a position in CRL in Q1 2014 and has held it in 36 quarters since. The position peaked at $3.38M in Q2 2018. 570 funds tracked by Wall St. Rank hold CRL as of Q2 2026.
- O'Shaughnessy Asset Management held 1,927 shares of Charles River Laboratories worth $437K as of Q2 2026.
- O'Shaughnessy Asset Management sold 1,818 Charles River Laboratories shares in Q2 2026, an estimated $324K.
- Charles River Laboratories made up ﹤0.01% of O'Shaughnessy Asset Management's portfolio in Q2 2026, its #1659 holding.
- O'Shaughnessy Asset Management first reported a position in Charles River Laboratories in Q1 2014 and has held it in 36 quarters since.
- O'Shaughnessy Asset Management's Charles River Laboratories position peaked at $3.38M in Q2 2018.
- 570 funds tracked by Wall St. Rank held Charles River Laboratories as of Q2 2026.
Based on O'Shaughnessy Asset Management's 13F filing for Q2 2026, filed 13 Aug 2026.